Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.530,84+0,73 %

Gold2.648,38-0,32 %

Öl (Brent)77,49-1,96 %

Dow Jones43.050,39+0,43 %

US Tech 10020.436,29+0,82 %

EUR/USD1,09024-0,32 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Clearside Biomedical Aktie

Aktie

ISIN: US1850631045 WKN: A2ALP6 SYM: CLM Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,1500

EUR

-4,96 %

-0,0600 EUR

Letzter Kurs 11.10.24 Tradegate

Geldkurs

18:50:46

1,0600

EUR

1.900 STK

Briefkurs

18:50:46

1,0900

EUR

2.000 STK

Clearside Biomedical Aktie kaufen

Neueste Nachrichten

Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 09.10.2024 09.10.24 · wO Chartvergleich · Commercial Metals
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes 09.10.24 · globenewswire · Clearside Biomedical
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD 27.08.24 · globenewswire · Clearside Biomedical
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update 12.08.24 · globenewswire · Clearside Biomedical
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 08.08.24 · globenewswire · Clearside Biomedical
Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 01.08.24 · globenewswire · Clearside Biomedical
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China 29.07.24 · globenewswire · Clearside Biomedical
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8: 00 am ET 22.07.24 · globenewswire · Clearside Biomedical
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board 11.07.24 · globenewswire · Clearside Biomedical
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery 27.06.24 · globenewswire · Clearside Biomedical
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting 12.06.24 · globenewswire · Clearside Biomedical
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injection in Leading Peer-Reviewed Industry Journal, RETINA 21.05.24 · globenewswire · Clearside Biomedical

1
2
…
3

Meistgelesen

7 Tage
30 Tage
12 Monate

Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 09.10.2024 884 Leser
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of ... 120 Leser

Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 09.10.2024 884 Leser
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of ... 120 Leser

Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 09.10.2024 884 Leser
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update 432 Leser
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ... 348 Leser
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update 300 Leser
Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 256 Leser
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via ... 216 Leser
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of ... 212 Leser
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering 180 Leser
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th ... 172 Leser
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD 156 Leser